A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

S Lheureux, A M Oza, S A Laurie, R Halford, D Jonker, E Chen, D Keller, V Bourade, L Wang, L Doyle, L L Siu, R Goel, S Lheureux, A M Oza, S A Laurie, R Halford, D Jonker, E Chen, D Keller, V Bourade, L Wang, L Doyle, L L Siu, R Goel

Abstract

Background: Eribulin mesylate is a synthetic microtubule inhibitor that showed cytotoxic synergy in combination with gemcitabine preclinically. This combination was assessed in a Phase I dose-finding trial in patients diagnosed with advanced solid tumours who had received up to two prior chemotherapy regimens for metastatic disease (CP cohort).

Methods: Dose escalation was performed in a 3+3 design to identify the recommended phase II dose (RP2D). Two additional expansion cohorts in women with gynaecologic cancers at the RP2D (G), and further dose escalation of metastatic chemotherapy-naive patients (CN), were evaluated.

Results: 45 patients were treated: 21 (CP), 10 (G) and 14 (CN). The initial combination of eribulin and gemcitabine was administered on days 1, 8, and 15 of a 28-day cycle; however, due to 2 out of 6 dose-limiting haematological toxicities at the first dose level, a reduced dose-intense schedule was assessed. The RP2D was defined at 1.0 mg m(-2) eribulin and 1000 mg m(-2) gemcitabine day 1 and 8 q3 weeks. No other significant toxicities were observed in the G expansion cohort. Neutropenia prevented further dose escalation in the CN cohort. Objective responses were seen in all three cohorts - 2/21 (CP), 1/10 (G) and 2/14 (CN).

Conclusions: The combination of eribulin and gemcitabine was well tolerated at the RP2D.

Trial registration: ClinicalTrials.gov NCT00410553.

Figures

Figure 1
Figure 1
Time on treatment for the all enroled patients (dose escalation and expansion cohort).

References

    1. Aapro MS, Martin C, Hatty S (1998) Gemcitabine--a safety review. Anticancer Drugs 9(3): 191–201.
    1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1944) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12(8): 1535–1540.
    1. Bookman MA (2005) Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15(Suppl 1): 12–17.
    1. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73(1): 101–105.
    1. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769): 914–923.
    1. Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, Blunt JW, Munro MH, Gussio R, Hamel E (2006) Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70(6): 1866–1875.
    1. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V (2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15(1): 19–27.
    1. Gornstein E, Schwarz TL (2014) The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology 76(Pt A): 175–183.
    1. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4(7): 1086–1095.
    1. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM (2014) Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer 111(12): 2268–2274.
    1. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64(16): 5760–5766.
    1. Kuznetsov G, Xu Q, Rudolph-Owen L, Tendyke K, Liu J, Towle M, Zhao N, Marsh J, Agoulnik S, Twine N, Parent L, Chen Z, Shie JL, Jiang Y, Zhang H, Du H, Boivin R, Wang Y, Romo D, Littlefield BA (2009) Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol Cancer Ther 8(5): 1250–1260.
    1. Lorusso V, Crucitta E, Silvestris N, Catino A, Caporusso L, Mazzei A, Guida M, Latorre A, Sambiasi D, D'Amico C, Schittulli F, Calabrese P, De Lena M (2003) Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. Br J Cancer 88(4): 491–495.
    1. Mattiucci GC, Ippolito E, D'Agostino GR, Alfieri S, Antinori A, Crucitti A, Balducci M, Deodato F, Luzi S, Macchia G, Smaniotto D, Morganti AG, Valentini V (2013) Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Ann Surg Oncol 20(2): 423–429.
    1. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5): v7–12.
    1. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7(7): 2003–2011.
    1. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(4 Suppl 11): 3–10.
    1. Polastro L, Aftimos PG, Awada A (2014) Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. Expert Rev Anticancer Ther 14(6): 649–665.
    1. Schöffski P, Maki RG, Italiano A, Gelderblom H, Grignani G, Pires De Camargo V, Bauer S, Young Rha S, Chawla SP, Blay JY, Hohenberger P, D'Adamo DR, Wang B, Chmielowski B, Le Cesne A, Demetri GD, Patel S (2015) Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol 33(Suppl): Abstr LBA10502.
    1. Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grünwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) (2011) Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 12(11): 1045–1052.
    1. Shablak A (2013) Eribulin for advanced breast cancer: a drug evaluation. J Breast Cancer 16(1): 12–15.
    1. Swami U, Chaudhary I, Ghalib MH, Goel S (2012) Eribulin -a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81(2): 163–184.
    1. Swami U, Shah U, Goel S (2015) Eribulin in cancer treatment. Mar Drugs 13(8): 5016–5058.
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205–216.
    1. Towle MJ, Agoulnik S, Kuznetsov G, TenDyke K, Reardon C, Cheng H, Zheng W, Seletsky BM, Palme MH, Kishi Y, Lewis MD, Yu MJ, Littlefield BA (2003) In vivo efficacy of E7389, a synthetic analogue of the marine sponge antitubulin agent halichondrin B, against human tumor xenografts under monotherapy and combination therapy conditions. Proc Am Assoc Cancer Res (AACR) 44 (2nd ed.) Abstract 2749.
    1. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61(3): 1013–1021.
    1. Vogelzang N, Conkling P, Duran I, Maroto J, Modiano M, De Leonardis P, Hodge JP, Lieberman R (2012) Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: Phase Ib results. J Clin Oncol 30(suppl 5): Abstract 273.
    1. Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17): 3068–3077.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi